Merck, known as MSD outside the United States and Canada, and Endocyte Inc., announced that the European Medicines Agency (EMA) has accepted for review the marketing authorization application (MAA) filings for the novel investigational cancer candidate vintafolide and investigational companion diagnostic imaging agent etarfolatide, for the targeted treatment of patients with folate-receptor positive platinum-resistant ovarian cancer in combination with pegylated liposomal doxorubicin (PLD). Both vintafolide and etarfolatide have been granted orphan drug status by the European Commission.

On November 27, 2012, the Company issued a press release announcing the acceptance for review the MAA filings, a copy of which press release is attached to this Current Report as Exhibit 99.1 and incorporated herein by reference.

(d) Exhibits

                Exhibit No.    Description

                      99.1     Press release dated November 27, 2012


--------------------------------------------------------------------------------
  Top of the Form